The emergence of SARS-CoV-2 variants with mutations in the spike protein is raising
concerns about the efficacy of infection-or vaccine-induced antibodies. We compared …

The rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
such as the Omicron variants that are highly transmissible and immune evasive …

Mutations in the spike glycoproteins of SARS-CoV-2 variants of concern have independently
been shown to enhance aspects of spike protein fitness. Here, we describe an antibody …

The 2019 coronavirus pandemic remains a major public health concern. Neutralizing
antibodies (nAbs) represent a cutting-edge antiviral strategy. We focus here on severe acute …

Tools to monitor SARS-CoV-2 transmission and immune responses are needed. We present
a neutralization ELISA to determine the levels of Ab-mediated virus neutralization and a …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …

A key goal of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surveillance
is to rapidly identify viral variants with mutations that reduce neutralization by polyclonal …

SARS-CoV-2 can mutate and evade immunity, with consequences for efficacy of emerging
vaccines and antibody therapeutics. Here, we demonstrate that the immunodominant SARS …

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants with increased transmissibility and potential resistance, antibodies and vaccines …

Monoclonal antibodies against the SARS-CoV-2 spike protein, notably, those developed by
Regeneron Pharmaceuticals and Eli Lilly and Company have proven to provide protection …